Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. They presently have a $767.00 target price on the biopharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 6.12% from the company’s current price.

REGN has been the subject of a number of other research reports. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $777.36.

Regeneron Pharmaceuticals Stock Down 0.1%

Shares of REGN opened at $722.80 on Wednesday. The firm has a market cap of $75.97 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 2.07 and a beta of 0.37. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $800.99. The company’s 50-day moving average price is $647.61 and its 200 day moving average price is $587.69. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the firm posted $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.